23775-42-0

Basic information

• Product Name: Cyclohexanamine, 4-(1-methylethyl)-, trans- (9CI)
• Synonyms: Cyclohexanamine, 4-(1-methylethyl)-, trans- (9CI)
• CAS NO: 23775-42-0
• Molecular Formula: C₉H₁₉N
• Molecular Weight: 141.25386
• Product Categories: VARIOUSAMINE
• Mol File: 23775-42-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 85-86 °C(Press: 20 Torr)
• Appearance: /
• Density: 0.850±0.06 g/cm3(Predicted)
• PKA: 10.57±0.70(Predicted)
• CAS DataBase Reference: Cyclohexanamine, 4-(1-methylethyl)-, trans- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanamine, 4-(1-methylethyl)-, trans- (9CI)(23775-42-0)
• EPA Substance Registry System: Cyclohexanamine, 4-(1-methylethyl)-, trans- (9CI)(23775-42-0)

Safety Data

• Hazardous Substances Data: 23775-42-0(Hazardous Substances Data)

Upstream product

• 133231-33-1 toluene-4-sulfonic acid-(cis-4-isopropyl-cyclohexyl ester) 
• 5432-85-9 4-isopropyl-cyclohexanone 
• 103027-46-9 4-Isopropylcyclohexanone oxime 
• 1087351-22-1 benzyl-(4-isopropylcyclohexyl)amine 

Downstream Products

• 19479-46-0 trans-4-Isopropyl-cyclohexyl-dimethylamin 

Relevant articles and documents

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.

TREATMENT OF CHAGAS DISEASE

The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of which being optionally substituted; R2 is H, methyl or ethyl; R5 is NRxCORy, NRxRy, CH2COCH3, CH2C≡N, or a 5- or 6-membered heteroaryl group which is optionally substituted; X, Y and Z are independently N or CH; Rx is independently H or C1-C4alkyl; Ry is independently H, CrC4alkyl, phenyl or benzyl, either of which is optionally substituted; n is 0-3; salts, hydrates and N-oxides, wherein the optional substituents are further defined in the claims. The compounds have utility in the prophylaxis or treatment of trypanosomal diseases, such as T. cruzi (Chagas disease).